Selected article for: "commercial kit and detection method"
Author: Jianghong An; Xuejiao Liao; Tongyang Xiao; Shen Qian; Jing Yuan; Haocheng Ye; Furong Qi; Chengguang Shen; Yang Liu; Lifei Wang; Xiaoya Cheng; Na Li; Qingxian Cai; Fang Wang; Jun Chen; Yingxia Liu; Yunfang Wang; Feng Zhang; Yang Fu; Xiaohua Tan; Lei Liu; Zheng Zhang
Title: Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test
  • Document date: 2020_3_30
    • ID: 58sc6xgq_4
    Snippet: This study retrospectively analyzed the clinical characteristics of 38 RP patients and 224 non-RP (NRP) patients recovered from COVID-19. It is found that RP patients were characterized by younger age and milder conditions. They also had minor symptoms, more sustained remission of CT imaging and earlier RNA negative-conversion but similar plasma antibody levels during their hospitalization period. They showed no obvious disease progression and in.....
    Document: This study retrospectively analyzed the clinical characteristics of 38 RP patients and 224 non-RP (NRP) patients recovered from COVID-19. It is found that RP patients were characterized by younger age and milder conditions. They also had minor symptoms, more sustained remission of CT imaging and earlier RNA negative-conversion but similar plasma antibody levels during their hospitalization period. They showed no obvious disease progression and infectivity when re-admitted to the hospital. The hyper-sensitive detection method identified SARS-CoV-2 RNA molecules from most samples that were tested RNA-negative by the commercial kit, suggesting the carrier status of virus possibly existed in recovering COVID-19 patients. These findings provide All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • carrier status and CT imaging: 1
    • carrier status and disease progression: 1
    • carrier status and hospitalization period: 1
    • carrier status and negative conversion: 1
    • carrier status and obvious disease progression: 1
    • clinical characteristic and commercial kit: 1
    • clinical characteristic and CT imaging: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical characteristic and disease progression: 1, 2, 3, 4, 5, 6
    • commercial kit and CT imaging: 1, 2
    • commercial kit and detection method: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • commercial kit and disease progression: 1, 2, 3, 4
    • commercial kit and hospitalization period: 1, 2, 3
    • commercial kit and hyper sensitive detection method: 1
    • commercial kit and negative conversion: 1, 2
    • commercial kit and obvious disease progression: 1, 2
    • CT imaging and hospitalization period: 1, 2, 3, 4, 5, 6, 7
    • CT imaging and hyper sensitive detection method: 1
    • CT imaging and negative conversion: 1, 2, 3, 4, 5, 6, 7
    • CT imaging and obvious disease progression: 1